EA202091302A1 - Замещенные азабициклы в качестве положительных аллостерических модуляторов мускаринового рецептора m1 - Google Patents

Замещенные азабициклы в качестве положительных аллостерических модуляторов мускаринового рецептора m1

Info

Publication number
EA202091302A1
EA202091302A1 EA202091302A EA202091302A EA202091302A1 EA 202091302 A1 EA202091302 A1 EA 202091302A1 EA 202091302 A EA202091302 A EA 202091302A EA 202091302 A EA202091302 A EA 202091302A EA 202091302 A1 EA202091302 A1 EA 202091302A1
Authority
EA
Eurasian Patent Office
Prior art keywords
positive allosteric
allosteric modulators
muscarine receptor
azabicycles
substituted
Prior art date
Application number
EA202091302A
Other languages
English (en)
Other versions
EA039902B1 (ru
Inventor
Рамакришна Нироджи
Анил Карбхари Схинде
Абдул Рашид Мохаммед
Раджеш Кумар Бадандже
Рагхава Чоудари Палачарла
Венкатесварлу Джасти
Original Assignee
Сувен Лайф Сайенсиз Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сувен Лайф Сайенсиз Лимитед filed Critical Сувен Лайф Сайенсиз Лимитед
Publication of EA202091302A1 publication Critical patent/EA202091302A1/ru
Publication of EA039902B1 publication Critical patent/EA039902B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Настоящее изобретение относится к соединениям формулы (I) или их изотопным формам, стереоизомерам, таутомерам или их фармацевтически приемлемым солям в качестве положительных аллостерических модуляторов мускаринового рецептора M1 (PAM M1). Настоящее изобретение описывает способы получения, фармацевтическую композицию, комбинации и применение соединения формулы (I), его стереоизомеров, изотопных форм или фармацевтически приемлемых солей.
EA202091302A 2017-11-23 2018-11-21 Замещенные азабициклы в качестве положительных аллостерических модуляторов мускаринового рецептора m1 EA039902B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201741042082 2017-11-23
PCT/IB2018/059164 WO2019102365A1 (en) 2017-11-23 2018-11-21 Substituted azacycles as muscarinic m1 receptor positive allosteric modulators

Publications (2)

Publication Number Publication Date
EA202091302A1 true EA202091302A1 (ru) 2020-08-17
EA039902B1 EA039902B1 (ru) 2022-03-25

Family

ID=64744766

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091302A EA039902B1 (ru) 2017-11-23 2018-11-21 Замещенные азабициклы в качестве положительных аллостерических модуляторов мускаринового рецептора m1

Country Status (19)

Country Link
US (1) US20210369685A1 (ru)
EP (1) EP3713940B1 (ru)
JP (1) JP7034284B2 (ru)
KR (1) KR102443402B1 (ru)
CN (1) CN111386270B (ru)
AU (1) AU2018372664B2 (ru)
BR (1) BR112020010138A2 (ru)
CA (1) CA3082724C (ru)
DK (1) DK3713940T3 (ru)
EA (1) EA039902B1 (ru)
HR (1) HRP20220736T1 (ru)
HU (1) HUE058954T2 (ru)
IL (1) IL274708B (ru)
MA (1) MA50806A (ru)
MX (1) MX2020005341A (ru)
NZ (1) NZ764561A (ru)
SG (1) SG11202004580WA (ru)
WO (1) WO2019102365A1 (ru)
ZA (1) ZA202002938B (ru)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697690B2 (en) 2010-07-01 2014-04-15 Merck Sharp & Dohme Corp. Isoindolone M1 receptor positive allosteric modulators
EP2709451B1 (en) * 2011-05-17 2015-12-30 Merck Sharp & Dohme Corp. N-linked lactam m1 receptor positive allosteric modulators
EP3639823A1 (en) * 2011-10-28 2020-04-22 Vanderbilt University Center for Technology Transfer and Commercialization Substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m1
NZ725921A (en) * 2014-04-23 2023-09-29 Takeda Pharmaceuticals Co Isoindoline-1-one derivatives as cholinergic muscarinic m1 receptor positive alloesteric modulator activity for the treatment of alzheimers disease
WO2017112719A1 (en) * 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 6,7-dihydro-5h-pyrrolo[3,4-b]pyridin-5-one allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018005249A1 (en) 2016-06-28 2018-01-04 Merck Sharp & Dohme Corp. Benzoisoquinolinone m1 receptor positive allosteric modulators

Also Published As

Publication number Publication date
EP3713940B1 (en) 2022-05-04
MX2020005341A (es) 2020-08-13
ZA202002938B (en) 2021-04-28
MA50806A (fr) 2020-09-30
KR20200090854A (ko) 2020-07-29
IL274708A (en) 2020-07-30
JP7034284B2 (ja) 2022-03-11
EP3713940A1 (en) 2020-09-30
AU2018372664B2 (en) 2020-11-19
CN111386270B (zh) 2022-05-03
CA3082724A1 (en) 2019-05-31
HRP20220736T1 (hr) 2022-09-02
WO2019102365A1 (en) 2019-05-31
BR112020010138A2 (pt) 2020-11-10
CA3082724C (en) 2022-05-31
NZ764561A (en) 2021-12-24
IL274708B (en) 2022-06-01
CN111386270A (zh) 2020-07-07
JP2021504357A (ja) 2021-02-15
EA039902B1 (ru) 2022-03-25
DK3713940T3 (da) 2022-06-20
SG11202004580WA (en) 2020-06-29
KR102443402B1 (ko) 2022-09-15
AU2018372664A1 (en) 2020-06-04
US20210369685A1 (en) 2021-12-02
HUE058954T2 (hu) 2022-10-28

Similar Documents

Publication Publication Date Title
MX2019002180A (es) Moduladores alostericos positivos del receptor m1 muscarinico.
EA202090486A2 (ru) Соединения для лечения спинальной мышечной атрофии
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
PH12016501440A1 (en) Novel heterocyclic compounds
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
EA201891179A1 (ru) N-замещенные индольные производные в качестве модуляторов pge2 рецепторов
MX2021002382A (es) Sales y formas cristalinas de modulador alosterico positivo gabaa.
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
EA201992679A1 (ru) N-замещенные индольные производные
EA202091256A1 (ru) Новые антагонисты рецептора брадикинина
EA201690888A1 (ru) Новые гетероциклические соединения
EA201792374A1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
EA201792594A1 (ru) Положительные аллостерические модуляторы мусаринового рецептора м1
EA201791600A1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
EA201590364A1 (ru) Применение орвепитанта, его солей и кристаллических форм и композиций, его содержащих, для лечения зуда
EA201890684A1 (ru) Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1
EA202092829A1 (ru) Композиции тофацитиниба с контролируемым высвобождением
EA201501163A1 (ru) Модуляторы рецептора cxcr7
EA202090995A1 (ru) Полициклические амиды в качестве положительных аллостерических модуляторов мускариновых рецепторов м1
EA202090925A1 (ru) Гетероарильные соединения в качестве позитивных аллостерических модуляторов мускаринового рецептора m1
EA201991045A1 (ru) Конденсированные азагетероциклические соединения и их применение в качестве модуляторов ampa-рецептора
EA202191046A1 (ru) Производные пирролопиридазина, как позитивные аллостерические модуляторы мускаринового рецептора m1
EA202091302A1 (ru) Замещенные азабициклы в качестве положительных аллостерических модуляторов мускаринового рецептора m1